During the last decade a large number of biological agents against tumor necrosis factor-α
(TNF-α), as well as many biochemical substances and molecules specifically for the medical …

Asthma affects nearly 300 million people worldwide. The majority respond to inhaled
corticosteroid treatment with or without beta-adrenergic agonists. However, a subset of 5 to …

BACKGROUND: Previous studies have identified clinical or inflammatory phenotypes of
asthma on the basis of clinical and demographic parameters or sputum cell counts; …

The chronic inflammatory response within the airways of asthmatics is associated with
structural changes termed airway remodeling. This remodeling process is a key feature of …

Bcl I in the promoter polymorphism observed within h-GR/NR3C1 gene may play an
important role in the development of bronchial asthma and resistance to GCs in the severe …

Corticosteroid insensitivity (CI) is a major barrier to treating severe asthma. Despite intensive
research, the molecular mechanism of CI remains uncertain. The aim of this study was to …

The disproportionate cost of treating asthmatic patients who do not respond to conventional
anti-inflammatory therapies makes delineation of the mechanism for glucocorticoid …

Currently available glucocorticoids are relatively short acting and may be less effective in
patients with chronic obstructive pulmonary disease (COPD) where high levels of oxidative …

The syndrome of generalized glucocorticoid (GC) resistance is a familial disorder that is
characterized by reduced cortisol effects, due to a GC receptor (GR) defect. This is …

Background In patients with prednisone-dependent asthma the dose of oral corticosteroids
should be adjusted to the lowest possible level to reduce long-term adverse effects …